DNA Screening In Every Corner Of South Carolina

South Carolina is blanketing all 46 of its counties with free DNA screening, aiming to catch deadly cancers and heart conditions before symptoms appear. The In Our DNA SC program, launched in partnership with the Medical University of South Carolina and private genomics firms, offers every resident—regardless of insurance or income—access to a saliva-based test that analyzes hundreds of genetic markers tied to elevated risk. This isn't a small pilot; it's a full-scale assault on the state's leading killers.

South Carolina has long struggled with high rates of cardiovascular disease and late-stage cancer diagnoses, particularly in rural and underserved communities. In Our DNA SC directly targets those disparities by taking the screening directly to community health centers, mobile clinics, and county fairs. The program is funded by a mix of state appropriations and philanthropic grants, making it free at the point of care.

The initiative screens for clinically actionable variants—changes in genes like BRCA1, BRCA2, and Lynch syndrome genes for cancer risk, as well as LDLR and APOB for familial hypercholesterolemia. When participants are flagged, they receive genetic counseling and a clear pathway to follow-up care. Early data from the first six counties showed that roughly 1 in 40 participants carried a high-risk variant they had never known about.

Dr. Donna Arnett, an epidemiologist at MUSC involved in the design, told local media that the program is ‘a game changer for preventive medicine in the South.’ By embedding genetic risk awareness into everyday primary care, South Carolina hopes to reduce the burden of late-stage disease and save millions in future treatment costs. The program also donates de-identified data to research registries, accelerating studies on population health.

What makes South Carolina DNA screening different from other statewide efforts is its insistence on geographic equity. Every county, from urban Greenville to remote Allendale, has at least one collection site. The logistics are daunting—sample transport, counseling capacity, data privacy—but early results suggest the model is scalable. If successful, it could become a template for other states grappling with chronic disease hot spots.

Next steps include expanding the panel to include pharmacogenomics—how your DNA affects medication response—and launching a public awareness campaign. The program is already fielding inquiries from health officials in Georgia, Mississippi, and Louisiana. For now, South Carolina is proving that genomic screening need not be a privilege of the wealthy; it can be a tool for everyone.